, Volume 17, Issue 4, pp 427–442 | Cite as

Functions of polymorphonuclear leukocytes in early rheumatoid arthritis

  • Marjatta Leirisalo-Repo
  • Leena Paimela
  • Saija Koskimies
  • Heikki Repo
Original Articles


We carried out a prospective study on clinical variables and functions of polymorphonuclear leukocytes (PMNs) of 20 patients with early rheumatoid arthritis (RA) and compared the results with the presence of erosions before treatment and at a one-year follow-up. Migration of PMNs determined by agarose and filter assays and respiratory burst of PMNs determined by luminol-enhanced chemiluminescence (CL) test were studied both before starting RA-modifying treatment and 6–12 (mean 7.3) months later. PMNs of the patients without erosions at one year, as compared to the patients with erosions, showed significantly depressed migration into filter and significantly depressed CL responses toN-formyl-methionyl-leucyl-phenylalanine, both before starting the treatment and at 7.3 months. Although causality remains uncertain, the results suggest that depressed functional capacity of PMNs is associated with low risk of joint destruction in early RA.


Public Health Rheumatoid Arthritis Arthritis Internal Medicine Agarose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Larsen, A., andJ. Thoen. 1987. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year.Scand. J. Rheumatol. 16:395–401.Google Scholar
  2. 2.
    Van Der Heijde, D. M. F. M., M. A. Van Leeuwen, P. L. C. M. Van Riel, A. M. Koster, M. A. Van't Hof, M. H. Van Rijswijk, andL. B. Van Der Putte. 1992. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis.Arthritis Rheum. 35:26–34.Google Scholar
  3. 3.
    Fleming, A., J. M. Crown, andM. Corbett. 1976. Prognostic value of early features in rheumatoid disease.Br. Med. J. 1:1243–1245.Google Scholar
  4. 4.
    Haataja, M., andL. J. KalliomÄki. 1978. Inter-relationship of laboratory variables in rheumatoid arthritis.J. Rheumatol. 5:263–266.Google Scholar
  5. 5.
    Möttönen, T. 1988. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis.Ann. Rheum. Dis. 47:648–653.Google Scholar
  6. 6.
    Dawes, P. T., P. D. Fowler, andR. Jackson. 1986. Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold orD-penicillamine therapy.Ann. Rheum. Dis. 45:945–949.Google Scholar
  7. 7.
    Capell, H. A., D. Lewis, andJ. Carey. 1986. A three-year follow-up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.Ann. Rheum. Dis. 45:705–711.Google Scholar
  8. 8.
    Harris, E. D., Jr. 1990. Rheumatoid arthritis. Pathophysiology and implications for therapy.N. Engl. J. Med. 322:1277–1289.Google Scholar
  9. 9.
    Mohr, W., H. Westerhellweg, andD. Wessinghage. 1981. Polymorphonuclear granulocytes in rheumatic tissue destruction. III. An electron microscopic study of PMNs at the pannuscartilage junction in rheumatoid arthritis.Ann. Rheum. Dis. 40:396–399.Google Scholar
  10. 10.
    Konttinen, Y. T., V. Bergroth, D. Nordström, K. Koota, B. Skrifvars, G. Hagman, C. Friman, M. HÄmÄlÄinen, andP. SlÄtis. 1985. Cellular immunohistopathology of acute, subacute and chronic synovitis in rheumatoid arthritis.Ann. Rheum. Dis. 44:549–555.Google Scholar
  11. 11.
    Jose, P. J., I. K. Moss, R. N. Maini, andT. J. Williams. 1990. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: Role of C5a in the acute inflammatory phase.Ann. Rheum. Dis. 49:747–752.Google Scholar
  12. 12.
    Weiss, S. J. 1989. Tissue destruction by neutrophils.N. Engl. J. Med. 320:365–376.Google Scholar
  13. 13.
    Mowat, A. G., andJ. Baum. 1971. Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.J. Clin. Invest. 50:2541–2549.Google Scholar
  14. 14.
    Roberts-Thompson, P. J., B. L. Hazlemann, I. G. Barnett, I. C. M. Maclennan, andA. G. Mowat. 1976. Factors relating to circulating immune complexes in rheumatoid arthritis.Ann. Rheum. Dis. 35:314–320.Google Scholar
  15. 15.
    Goddard, D. H., A. P. Kirk, J. R. Kirwan, G. D. Johnson, andE. J. Holborow. 1984. Impaired polymorphonuclear leukocyte chemotaxis in rheumatoid arthritis.Ann. Rheum. Dis. 43:151–156.Google Scholar
  16. 16.
    Elmgren, J., andT. H. Hansen. 1985. Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: Relation to complement catabolism and disease extent.Ann. Rheum. Dis. 44:514–518.Google Scholar
  17. 17.
    Turner, R. A., J. A. Johnson, andS. R. Turner. 1987. Neutrophil responsiveness to chemoattractant tripeptide in rheumatoid arthritis.Proc. Soc. Exp. Biol. Med. 186:125–133.Google Scholar
  18. 18.
    Howe, G. B., J. N. Fordham, K. A. Brown, andH. L. F. Currey. 1981. Polymorphonuclear cell function in rheumatoid arthritis and Felly's syndrome.Ann. Rheum. Dis. 40:370–375.Google Scholar
  19. 19.
    King, S. L., J. Parker, R. Cooper, R. Sturrock, andC. G. Gemmel. 1986. Polymorphonuclear leucocyte function in rheumatoid arthritis.Br. J. Rheumatol. 25:26–33.Google Scholar
  20. 20.
    Brown, K. A. 1988. The polymorphonuclear cell in rheumatoid arthritis.Br. J. Rheumatol. 27:150–155.Google Scholar
  21. 21.
    Espersen, G. T., E. Ernst, M. Vestergaard, J. O. Pedersen, andN. Grunnet. 1989. Changes in PMN leukocyte migration activity and complement C3d levels in RA patients with high disease activity during steroid treatment.Scand. J. Rheumatol. 18:51–56.Google Scholar
  22. 22.
    Chiu, P. L., P. Davis, K. Wong, andM. Dasgupta. 1983. Superoxide production in neutrophils of patients with rheumatoid arthritis and Felly's syndrome.J. Rheumatol. 10:694–700.Google Scholar
  23. 23.
    Davis, P., andC. Johnston. 1986. Effects of gold compounds on function of phagocytic cells. Comparative inhibition of activated polymorphonuclear leukocytes and monocytes from rheumatoid arthritis and control subjects.Inflammation 10:311–320.Google Scholar
  24. 24.
    Biemond, P., A. J. G. Swaak, J. M. A. Penders, C. M. Beindorf, andJ. F. Koster. 1986. Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: In vivo inhibition by antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase.Ann. Rheum. Dis. 45:249–255.Google Scholar
  25. 25.
    Ropes, M. W., G. A. Bennett, S. Cobb, R. Jacox, andR. A. Jessar. 1958. 1958 revision of diagnostic criteria for rheumatoid arthritis.Bull. Rheum. Dis. 9:175–176.Google Scholar
  26. 24.
    Ritchie, D. M., J. A. Boyle, J. M. McInnes, M. K. Jasani, T. G. Dalakos, P. Grieveson, andW. W. Buchanan. 1968. Clinical studies with an articular index to assessment of joint tenderness in patients with rheumatoid arthritis.Q. J. Med. 37:393–406.Google Scholar
  27. 27.
    Scott, J., andE. C. Huskisson. 1976. Graphic representation of pain.Pain 2:175–184.Google Scholar
  28. 28.
    Twomey, B. M., andM. M. Dale. 1992. Cyclooxygenase-independent effects of non-steroidal anti-inflammatory drags on the neutrophil respiratory burst.Biochem. Pharmacol. 43:413–418.Google Scholar
  29. 29.
    Repo, H., L. Saxen, M. JÄÄttelÄ, M. Ristola, andM. Leirisalo-Repo. 1990. Phagocyte function in juvenile periodontitis.Infect. Immun. 58:1085–1092.Google Scholar
  30. 30.
    Repo, H., E. Savilahti, andM. Leirisalo-Repo. 1987. Aberrant phagocyte function in Shwachman syndrome.Clin. Exp. Immunol. 69:204–212.Google Scholar
  31. 31.
    Zigmond, S. H., andJ. Hirsch. 1973. Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.J. Exp. Med. 137:387–410.Google Scholar
  32. 32.
    Boyden, S. 1962. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes.J. Exp. Med. 115:453–466.Google Scholar
  33. 33.
    Wilkinson, P. C. 1974. Chemotaxis and Inflammation. Edinburgh, Churchill Livingstone, Ltd. 168–171.Google Scholar
  34. 34.
    Koivuranta-Vaara, P., M. Leirisalo-Repo, andH. Repo. 1987. Polymorphonuclear leucocyte function and previous yersinia arthritis: Enhanced chemokinetic migration and oxygen radical production correlate with the severity of the acute disease.Ann. Rheum. Dis. 46:307–313.Google Scholar
  35. 35.
    Pincus, T. 1988. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials.J. Clin. Epidemiol. 41:1037–1041.Google Scholar
  36. 36.
    Reeback, J., andA. Silman. 1984. Predictors of outcome at two years in patients with rheumatoid arthritis.J. R. Soc. Med. 77:1002–1005.Google Scholar
  37. 37.
    Pamela, L., P. Kurki, T. Helve, andM. Leirisalo-Repo. 1991. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis.Arthritis Rheum. 34:815–821.Google Scholar
  38. 38.
    Baccino, E., J. M. Harrewyn, J. Jouquan, H. Swirsky, L. Bressolette, D. Mottier, andP. Youinou. 1987. Ketoprofen-induced reduction of polymorphonuclear cell activation in rheumatoid arthritis.Clin. Exp. Rheumatol. 5:53–57.Google Scholar
  39. 39.
    Turner, R. A., J. A. Johnson, S. R. Turner, M. Mcgee, andF. Kashanian. 1990. Neutrophil functional and arachidonic acid metabolic correlates and clinical disease activity in pirazolac-treated rheumatoid arthritis patients.Drugs Exp. Clin. Res. 16:39–48.Google Scholar
  40. 40.
    Repo, H., A. M. M. Jokipii, M. Leirisalo, andT. U. Kosunen. 1980. Leucocyte motility in the newborn: Determination of spontaneous movement is essential in the in vitro assessment of neutrophil chemotaxis.Clin. Exp. Immunol. 40:620–626.Google Scholar
  41. 41.
    Repo, H., P. Vuopio, M. Leirisalo, S.-E. Jansson, andT. U. Kosunen. 1979. Impaired neutrophil chemotaxis in Pelger-Huet anomaly.Clin. Exp. Immunol. 36:326–333.Google Scholar
  42. 42.
    Wilkinson, P. C. 1987. Leucocyte locomotion: behavioural mechanisms for accumulation.J. Cell. Sci. 8(Suppl):103–119.Google Scholar
  43. 43.
    Wilkinson, P. C., andW. S. Haston. 1988. Chemotaxis: An overview.Methods Enzymol. 162:3–16.Google Scholar
  44. 44.
    Perussia, B., M. Kobayashi, M. E. Rossi, I. Anegon, andG. Trinchieri. 1987. Immune Interferon enhances functional properties of human granulocytes: Role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor.J. Immunol. 138:765–774.Google Scholar
  45. 45.
    Khwaja, A., J. E. Carver, andD. C. Lich. 1992. Interactions of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor necrosis factor alpha in the priming of the neutrophil respiratory burst.Blood 79:745–753.Google Scholar
  46. 46.
    Cassatella, M. A., F. Bazzoni, R. M. Flynn, S. Dusi, G. Trinchieri, andF. Rossi. 1990. Molecular basis of interferon-gamma and lipopolysaccharide enhancement of phagocyte respiratory burst capability.J. Biol. Chem. 265:20241–20246.Google Scholar
  47. 47.
    Sadouk, M., C. Vaqueho, B. De La Tour, B. Amor, andA. Toubert. 1990. Interferongamma mRNA expression upon in vitro T lymphocyte activation is decreased in rheumatoid arthritis patients.Clin. Immunol. Immunopathol. 56:37–45.Google Scholar
  48. 48.
    Gale, R. J., A. Nikoloutsopoulos, J. Bradley, andP. J. Roberts-Thomson. 1985. Immune complex activation of neutrophils and enhancement of the activation by rheumatoid factor and complement.J. Rhewnatol. 12:21–26.Google Scholar
  49. 49.
    Dechatelet, L. R., G. D. Long, P. S. Shirley, D. A. Bass, M. J. Thomas, F. W. Hen-Derson, andM. S. Cohen. 1982. Mechanism of the luminol-dependent chemiluminescence of human neutrophils.J. Immunol. 129:1589–1593.Google Scholar
  50. 50.
    Edwards, S. W. 1987. Luminol- and lucigenin-dependent chemiluminescence of neutrophils: Role of degranulation.J. Clin. Lab. Immunol. 22:35–39.Google Scholar
  51. 51.
    Dahlgren, C., andR. Lock. 1988. The limitation of the human neutrophil chemiluminescence response by extracellular peroxidase is stimulus dependent: Effect of added horse radish peroxidase on the response induced by both soluble and particulate stimuli.J. Clin. Lab. Immunol. 26:49–53.Google Scholar
  52. 52.
    Dahlgren, C. 1988. Effects on extra- and intracellularly localized, chemoattractant-induced, oxygen radical production in neutrophils following modulation of conditions for ligand-receptor interaction.Inflammation 12:335–349.Google Scholar
  53. 53.
    Edwards, S. W., V. Hughes, J. Barlow, andR. Bucknall. 1988. Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis.Biochem. J. 250:81–85.Google Scholar
  54. 54.
    Davies, E. V., B. D. Williams, andA. K. Campbell. 1990. Synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis have reduced MPO and NADPH-oxidase activity.Br. J. Rheumatol. 29:415–421.Google Scholar
  55. 55.
    Minta, J. O., andM. D. Williams. 1986. Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes.J. Rheumatol. 13:498–504.Google Scholar
  56. 56.
    Cuperus, R. A., A. O. Muijsers, andR. Wever. 1985. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis?Arthritis Rheum. 28:1228–1233.Google Scholar
  57. 57.
    Mege, J. L., C. Capo, P. Bongrand, P. Richard, andH. Roux. 1986. RÔle des cellules phagocytaires dans la polyarthrite rhumatoÏde.Rev. Rhum. Mal. Osteoartic. 53:55–58.Google Scholar

Copyright information

© Plenum Publishing Corporation 1993

Authors and Affiliations

  • Marjatta Leirisalo-Repo
    • 1
    • 2
  • Leena Paimela
    • 3
  • Saija Koskimies
    • 4
  • Heikki Repo
    • 1
    • 2
  1. 1.Department of Bacteriology and ImmunologyUniversity of HelsinkiHelsinkiFinland
  2. 2.Second Department of MedicineUniversity of HelsinkiHelsinkiFinland
  3. 3.KivelÄ HospitalHelsinkiFinland
  4. 4.Finnish Red Cross Blood Transfusion ServiceHelsinkiFinland

Personalised recommendations